Autor: |
Chin-Shiang Tsai, Susan Shin-Jung Lee, Wan-Chen Chen, Chien-Hao Tseng, Nan-Yao Lee, Po-Lin Chen, Ming-Chi Li, Ling-Shan Syue, Ching-Lung Lo, Wen-Chien Ko, Yuan-Pin Hung |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Journal of Microbiology, Immunology and Infection, Vol 56, Iss 4, Pp 672-679 (2023) |
Druh dokumentu: |
article |
ISSN: |
1684-1182 |
DOI: |
10.1016/j.jmii.2022.12.002 |
Popis: |
The incidence of COVID-19-associated candidiasis (CAC) is increasing, resulting in a grave outcome among hospitalized patients with COVID-19. The most alarming condition is the increasing incidence of multi-drug resistant Candida auris infections among patients with COVID-19 worldwide. The therapeutic strategy towards CAC caused by common Candida species, such as Candida albicans, Candida tropicalis, and Candida glabrata, is similar to the pre-pandemic era. For non-critically ill patients or those with a low risk of azole resistance, fluconazole remains the drug of choice for candidemia. For critically ill patients, those with a history of recent azole exposure or with a high risk of fluconazole resistance, echinocandins are recommended as the first-line therapy. Several novel therapeutic agents alone or in combination with traditional antifungal agents for candidiasis are potential options in the future. However, for multidrug-resistant C. auris infection, only echinocandins are effective. Infection prevention and control policies, including strict isolation of the patients carrying C. auris and regular screening of non-affected patients, are suggested to prevent the spread of C. auris among patients with COVID-19. Whole-genome sequencing may be used to understand the epidemiology of healthcare-associated candidiasis and to better control and prevent these infections. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|